Terapia Génica en Enfermedad de Parkinson
PARKBA SAL
Instituto de Neurociencias del Principado de Asturias
Oviedo, EspañaPublikationen in Zusammenarbeit mit Forschern von Instituto de Neurociencias del Principado de Asturias (3)
2020
-
Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164
-
Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum
Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42
2019
-
Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease
Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910